

Preventative Service	Procedure/HCPCS	Description of Service	Modifier (if applicable)	Revenue Code	Applicable Diagnosis	Diagnosis Description	Frequency	Age	Notes
<a href="http://www.stdtaf.org">www.stdtaf.org</a>					Diagnosis code used for all exams		<a href="http://www.cdc.gov">www.cdc.gov</a>		
<b>Mammogram</b>	77067	Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed		403	Z12.31	Encounter for screening mammogram for malignant neoplasm of breast	Every 1 to 2 years for women over 40	40 +	
	77063	<b>Add on Code -</b> Screening digital breast tomosynthesis, bilateral (bill in conjunction with 77067)		403	Z12.39	Encounter for other screening for malignant neoplasm of breast			
<b>*Commercial Members Only</b>	77061	Digital Breast Tomosynthesis; Unilateral			Z12.31		annual	40 +	*women at average risk of breast cancer start mammography at 45. Annual mammograms 45 - 54, and continue to undergo mammography every one to two years. <a href="https://www.cancer.org">https://www.cancer.org</a>
	77062	Digital Breast Tomosynthesis; Bilateral			Z12.39		annual	40 +	
					Diagnosis code used for all exams				
<b>Chemoprevention of Breast Cancer</b>	99401	Preventive counseling or risk factor reduction: 15 mins	33	510	Z15.01*		varies	35 +	Z15.01 not acceptable principle diagnosis
<b>* used in absence of a wellness exam</b>	99402	Preventive counseling or risk factor reduction: 30 min	33	510	Z80.3			35 +	Recommendation applies to asymptomatic women aged 35 yrs. or older without a prior diagnosis of breast cancer
<b>*Codes not covered by Medicaid</b>	99403	Preventive counseling or risk factor reduction: 45 mins	33	510	D24.1			35 +	
	99404	Preventive counseling or risk factor reduction: 60 mins	33	510	D24.2			35 +	
					D24.5				
					N60.81				
					N60.82				
					N60.89				
<b>Osteoporosis</b>	77080	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)		32X	Z13.820	Encounter for screening for Osteoporosis		65 +	Recommendation use DEXA Scans for testing
	77081	appendicular skeleton (peripheral) (eg, radius, wrist, heel)		32X	Z13.820	Encounter for screening for Osteoporosis			Screen younger women whose fracture risk is equal to or greater than a 65-year old
					Diagnosis codes used for all wellness exams				
<b>Well Woman Visits</b>	S0610	Annual gynecological exam, NP		510	Z00.00	Encounter for general adult medical exam without abnormal findings	Once every 3 years	21 +	
<b>*Medicare &amp; some Commercial Payers</b>	S0612	Annual gynecological exam, EP		510	Z00.01	Encounter for general adult medical exam with abnormal findings	Annual	21 +	
	S0613	Annual gynecological examination; clinical breast exam without pelvic evaluation		510	Z01.411	Encounter for gynecological exam (general) (routine) with abnormal findings	Annual	21 +	
					Z01.419	Encounter for gynecological exam (general) (routine) without abnormal findings			
					Diagnosis codes used for pap test				
<b>Lab Services</b>	Q0091	Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory			Z12.4	Encounter for screening for malignant neoplasm of cervix (excludes HPV)	ages 21-29 every 3 years, ages 30-64 every 3 years or a combo of a pap smear and HPV test every 5 years. 65 and older ask physician. <a href="http://www.womenshealth.gov">www.womenshealth.gov</a>	21 +	if you get an abnormal Pap smear result, you may need to be screened more frequently for some time after that
<b>*collection of a cervical specimen via a pelvic examination is included in the preventive medicine service code (99381, 99385 and 99391, 99395)</b>					Z12.72	Encounter for screening for malignant neoplasm of vagina			
					Z12.79	encounter for screening for malignant neoplasm of other genitourinary organs			
					Z12.89	Encounter for screening for malignant neoplasms of other sites			
					Diagnosis codes used for all labs				
<b>Screening for gonorrhea for women</b>	87590	Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoea, direct probe technique			Z11.59	Encounter for screening for other viral diseases	Sexually active women under 25 years of age - retest approx 3 months after treatment	up to 24 years	
	87591	Infectious agent detection by nucleic acid (DNA or RNA); N gonorrhoea, amplified probe technique			Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission (excludes HPV and HIV)	Sexually active women under 25 years of age - retest approx 3 months after treatment	up to 24 years	
<b>Screening for cholesterol abnormalities</b>	80061	Lipid panel			Z13.220	Encounter for screening for lipid disorders	annual	20 +	for lipid disorders if they are at increased risk for coronary heart disease
					Diagnosis codes used for all labs				
<b>Chlamydia Screening in Women</b>	87110	Culture, chlamydia, any source			Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission (excludes HPV and HIV)	Sexually active women under 25 years of age - retest approx 3 months after treatment	16 - 24 years	*women 16-24 years of age who were identified as sexually active
<b>*women 16-24 years of age who were identified as sexually active</b>	87270	Chlamydia trachomatis			Z11.8	Encounter for screening for other infectious and parasitic diseases (eg, chlamydia)	Sexually active women under 25 years of age - retest approx 3 months after treatment	16 - 24 years	*women 16-24 years of age who were identified as sexually active
	87490	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique					Sexually active women under 25 years of age - retest approx 3 months after treatment	16 - 24 years	*women 16-24 years of age who were identified as sexually active
	87491	Infectious agent detection by nucleic acid (DNA or RNA); C trachomatis, amplified probe technique					Sexually active women under 25 years of age - retest approx 3 months after treatment	16 - 24 years	*women 16-24 years of age who were identified as sexually active
	87492	Chlamydia trachomatis, quantification					Sexually active women under 25 years of age - retest approx 3 months after treatment	16 - 24 years	*women 16-24 years of age who were identified as sexually active